SeaStar Medical's Novel QUELIMMUNE Therapy Offers Hope for Pediatric Acute Kidney Injury Patients

SeaStar's QUELIMMUNE Therapy For Pediatric AKI Adopted By Hospitals In Multiple States, Adult Treatment In Pipeline

By Meg Flippin Benzinga DETROIT, MICHIGAN - May 12, 2025 (NEWMEDIAWIRE) - Pediatric acute kidney injury (AKI) impacts approximately 4,000 children in the U.S. each year, and the prognosis for these patients is grim. The mortality rate is 50%, they spend twice as long in the ICU, and more than 30% will develop chronic kidney disease following AKI - noted SeaStar Medical in its recent investor presentation. Yet finding effective treatments doesn’t…

SeaStar Medical's Novel QUELIMMUNE Therapy Offers Hope for Pediatric Acute Kidney Injury Patients

A new therapeutic approach is showing promising results in treating pediatric acute kidney injury (AKI), with potential to transform patient outcomes and reduce healthcare costs. SeaStar Medical’s QUELIMMUNE therapy, recently approved by the FDA under a Humanitarian Device Exemption, offers hope for children facing this serious medical condition. Pediatric AKI impacts approximately 4,000 children annually in the United States, with a mortality r…